Literature DB >> 31220673

Synthesis and biological evaluation of indoloquinoline alkaloid cryptolepine and its bromo-derivative as dual cholinesterase inhibitors.

Vijay K Nuthakki1, Ramesh Mudududdla2, Ankita Sharma3, Ajay Kumar3, Sandip B Bharate4.   

Abstract

Alkaloids have always been a great source of cholinesterase inhibitors. Numerous studies have shown that inhibiting acetylcholinesterase as well as butyrylcholinetserase is advantageous, and have better chances of success in preclinical/ clinical settings. With the objective to discover dual cholinesterase inhibitors, herein we report synthesis and biological evaluation of indoloquinoline alkaloid cryptolepine (1) and its bromo-derivative 2. Our study has shown that cryptolepine (1) and its 2-bromo-derivative 2 are dual inhibitors of acetylcholinesterase and butyrylcholinesterase, the enzymes which are involved in blocking the process of neurotransmission. Cryptolepine inhibits Electrophorus electricus acetylcholinesterase, recombinant human acetylcholinesterase and equine serum butyrylcholinesterase with IC50 values of 267, 485 and 699 nM, respectively. The 2-bromo-derivative of cryptolepine also showed inhibition of these enzymes, with IC50 values of 415, 868 and 770 nM, respectively. The kinetic studies revealed that cryptolepine inhibits human acetylcholinesterase in a non-competitive manner, with ki value of 0.88 µM. Additionally, these alkaloids were also tested against two other important pathological events of Alzheimer's disease viz. stopping the formation of toxic amyloid-β oligomers (via inhibition of BACE-1), and increasing the amyloid-β clearance (via P-gp induction). Cryptolepine displayed potent P-gp induction activity at 100 nM, in P-gp overexpressing adenocarcinoma LS-180 cells and excellent toxicity window in LS-180 as well as in human neuroblastoma SH-SY5Y cell line. The molecular modeling studies with AChE and BChE have shown that both alkaloids were tightly packed inside the active site gorge (site 1) via multiple π-π and cation-π interactions. Both inhibitors have shown interaction with the allosteric "peripheral anionic site" via hydrophobic interactions. The ADME properties including the BBB permeability were computed for these alkaloids, and were found within the acceptable range.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acetylcholinesterase; Alzheimer's disease; Butyrylcholinesterase; Cryptolepine; Dual cholinesterase inhibitor

Mesh:

Substances:

Year:  2019        PMID: 31220673     DOI: 10.1016/j.bioorg.2019.103062

Source DB:  PubMed          Journal:  Bioorg Chem        ISSN: 0045-2068            Impact factor:   5.275


  4 in total

1.  Recent Advances in the Chemistry and Pharmacology of Cryptolepine.

Authors:  Steven D Shnyder; Colin W Wright
Journal:  Prog Chem Org Nat Prod       Date:  2021

2.  Malononitrile-activated synthesis and anti-cholinesterase activity of styrylquinoxalin-2(1H)-ones.

Authors:  Sheena Mahajan; Nancy Slathia; Vijay K Nuthakki; Sandip B Bharate; Kamal K Kapoor
Journal:  RSC Adv       Date:  2020-04-21       Impact factor: 4.036

Review 3.  Unravelling the pharmacological properties of cryptolepine and its derivatives: a mini-review insight.

Authors:  Champa Keeya Tudu; Anustup Bandyopadhyay; Manoj Kumar; Tuyelee Das; Samapika Nandy; Mimosa Ghorai; Abilash Valsala Gopalakrishnan; Jarosław Proćków; Abhijit Dey
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-10-17       Impact factor: 3.195

4.  Discovery of Helminthosporin, an Anthraquinone Isolated from Rumex abyssinicus Jacq as a Dual Cholinesterase Inhibitor.

Authors:  Ntemafack Augustin; Vijay K Nuthakki; Mohd Abdullaha; Qazi Parvaiz Hassan; Sumit G Gandhi; Sandip B Bharate
Journal:  ACS Omega       Date:  2020-01-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.